Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer

This research study analyzes stored blood samples from people with pancreatic cancer to see if tiny molecules called microRNAs (found in particles released by tumor cells) can predict how well someone responded to chemotherapy given before surgery. It is not a treatment trial — it uses samples already collected. **You may be eligible if...** - You have been confirmed to have pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer) - You received chemotherapy (FOLFIRINOX or gemcitabine/nab-paclitaxel) before surgery - Blood samples were taken before your treatment started - You had surgery with the intent to remove the tumor **You may NOT be eligible if...** - Your blood samples are unavailable or of poor quality - You have a different type of pancreatic cancer (not adenocarcinoma) - You have or had another primary cancer at the same time - You received a non-standard chemotherapy regimen - You have an active inflammatory or autoimmune disease Talk to your doctor to see if this trial is right for you.